Health and Fitness Health and Fitness
Mon, October 18, 2010
[ Mon, Oct 18th 2010 ] - Market Wire
Synta Pharmaceuticals to Present at the Newsmakers in Biotechnology Conference
[ Mon, Oct 18th 2010 ] - Market Wire
Apricus Bio Announces First Patent Grant for Femprox® In Japan
[ Mon, Oct 18th 2010 ] - Market Wire
Bronstein, Gewirtz & Grossman, LLC Investigating .. s Law Violations at Gentiva Health Services, Inc.
[ Mon, Oct 18th 2010 ] - Market Wire
LifePoint Hospitals to Broadcast Its Third Quarter 2010 Conference Call Live on the Internet
[ Mon, Oct 18th 2010 ] - Market Wire
The Briscoe Law Firm Investigates AGA Medical Hol .. , Inc. Concerning the Buy-Out by St. Jude Medical
[ Mon, Oct 18th 2010 ] - Market Wire
American CareSource Holdings Adds Insurance Management Administrators Client Portfolio
[ Mon, Oct 18th 2010 ] - Market Wire
Faruqi & Faruqi, LLP Announces Investigation Rela .. Acquisition of AGA Medical Holdings, Inc. - AGAM
[ Mon, Oct 18th 2010 ] - Market Wire
Kendall Law Group Investigates AGA Medical Holdings, Inc. Acquisition for Shareholders
[ Mon, Oct 18th 2010 ] - Market Wire
U.S. Food and Drug Administration Approves BARACL .. nt for Chronic Hepatitis B Patients with Evidence
[ Mon, Oct 18th 2010 ] - Market Wire
Teva Announces Launch of Generic Prevacid® SoluTab in the United States
[ Mon, Oct 18th 2010 ] - Market Wire
Tenet Hospitals Awarded 205 CIGNA HealthCare Quality Designations
[ Mon, Oct 18th 2010 ] - Market Wire
Zynex Increases Board of Directors
[ Mon, Oct 18th 2010 ] - Market Wire
Thermo Fisher Scientific Forms Scientific Advisory Board
[ Mon, Oct 18th 2010 ] - Market Wire
XIFAXAN 550 mg (Rifaximin) Demonstrates Acute and .. stipation Irritable Bowel Syndrome Symptoms: Data
[ Mon, Oct 18th 2010 ] - Market Wire
Mergenet Medical Launches Trach-Assist® First Airway Secretion Management System of Its Kind
[ Mon, Oct 18th 2010 ] - Market Wire
Micromet to Present at the 2010 Newsmakers in the Biotechnology Industry Conference
[ Mon, Oct 18th 2010 ] - Market Wire
BioScrip, Inc. to Host 2010 Third Quarter Earnings Call
[ Mon, Oct 18th 2010 ] - Market Wire
Gegevens ter verdere ondersteuning van onderzoek .. en gepresenteeerd op het 26ste congress van het E
[ Mon, Oct 18th 2010 ] - Market Wire
GenMark Diagnostics Schedules Third Quarter Earni .. Release and Conference Call for November 4, 2010
[ Mon, Oct 18th 2010 ] - Market Wire
Vertex Pharmaceuticals Initiates Clinical Trial t .. ns of VX-770 and VX-809 Targeting the Defective P
[ Mon, Oct 18th 2010 ] - Market Wire
Lannett Company Launches Fluphenazine HCl Tablets USP
[ Mon, Oct 18th 2010 ] - Market Wire
BioSante Pharmaceuticals Reaches Key LibiGel® Safety Study Enrollment Target
[ Mon, Oct 18th 2010 ] - Market Wire
Celgene Corporation to Announce Third Quarter 2010 Results on October 28, 2010
[ Mon, Oct 18th 2010 ] - Market Wire
Presentacin de nuevos datos que apoyan el ensayo .. 26 Congreso del Comit© Europeo para el tratamien
[ Mon, Oct 18th 2010 ] - Market Wire
St. Jude Medical and AGA Medical Announce Definitive Agreement
[ Mon, Oct 18th 2010 ] - Market Wire
BioCryst Pharmaceuticals to Announce Third Quarter 2010 Financial Results on October 28, 2010
Sun, October 17, 2010
[ Sun, Oct 17th 2010 ] - Market Wire
Neue Daten, die einen mglichen Nutzen des JC-Viru .. den auf dem 26. Kongress des European Committee f
Sat, October 16, 2010
[ Sat, Oct 16th 2010 ] - Market Wire
Des donn©es soutenant l'essai clinique sur les a .. ©es lors du 26e Congrs du Comit© europ©en pour
[ Sat, Oct 16th 2010 ] - Market Wire
Celgene voltooit acquisitie van Abraxis
[ Sat, Oct 16th 2010 ] - Market Wire
Presentati dati che confermano ulteriormente anal .. JC in occasione del 26o Congresso del Comitato e

Presentati dati che confermano ulteriormente analisi su anticorpi contro virus JC in occasione del 26o Congresso del Comitato e


Published on 2010-10-16 02:40:42 - Market Wire
  Print publication without navigation


GOTHENBURG, Svezia--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) ed [ Elan Corporation ], plc (NYSE: ELN) hanno annunciato oggi ulteriori dati che confermano la potenziale utilit clinica di un'analisi investigativa che localizzi anticorpi contro il virus JC (JCV) nel plasma o nel siero umani. La localizzazione di anticorpi anti-JVC potrebbe fornire un modo di segmentare o stratificare i pazienti affetti da sclerosi multipla (SM) per cui si sta prendendo in considerazione o a cui viene gi somministrato il trattamento con TYSABRI® (natalizumab) e di valutare i loro rischi di sviluppare leucoencefalopatia multifocale (PML), una rara ma grave infezione al cervello.

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.

Contributing Sources